DIVISLAB · Divi's Laboratories Ltd · Biotechnology & Drugs
DIVISLAB · Divi's Laboratories Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
0.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹3,080 Cr
Revenue YoY
PAT YoY
+65.5%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
14.5
P/S (TTM)
21.4
Sector P/E
46.9
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| DIVISLAB (this stock) | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
| Cipla | 35.1 | 4 | +11.9% | +9.8% | 0.02 | +0.9% |
Promoter
stable
FII
rising 1q
MF
14.66% (+0.79pp)
rising 2q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 30 Sept 2026 | L. Sri Lakshmi | BUY | 162 | ₹15.27 lakh |
| 30 Sept 2026 | D Radhika | BUY | 300 | ₹27.97 lakh |
| 29 Sept 2026 | Nimmagadda Venkata Anirudh | SELL | 3,500 | ₹3.33 Cr |
| 29 Sept 2026 | Joshita Divi | BUY | 1,005 | ₹96.13 lakh |
| 25 Sept 2026 | L. Sri Lakshmi | BUY | 603 | ₹57.87 lakh |
| 11 Sept 2026 | PRASAD Y.T.S. | SELL | 6,234 | ₹5.84 Cr |
| 11 Sept 2026 | PRASAD Y.T.S. | SELL | 2,000 | ₹1.86 Cr |
| 10 Sept 2026 | PRASAD Y.T.S. | SELL | 734 | ₹69.28 lakh |
| 08 Sept 2026 | K. Sridevi | SELL | 200 | ₹18.99 lakh |
| 07 Sept 2026 | K. Sridevi | SELL | 200 | ₹18.56 lakh |
| 28 Aug 2026 | K. Sridevi | SELL | 200 | ₹18.5 lakh |
| 19 Aug 2026 | P. JITENDRA | BUY | 1,575 | ₹1.35 Cr |
| 11 Aug 2026 | K. Sridevi | SELL | 200 | ₹16.95 lakh |
| 11 Aug 2026 | Divi Madhusudana Rao | SELL | 20,000 | ₹16.83 Cr |
| 30 Jun 2026 | Nimmagadda Venkata Anirudh | SELL | 4,200 | ₹2.75 Cr |
| 29 Jun 2026 | Donepudi Venkata Sohini | BUY | 351 | ₹23.51 lakh |
| 29 Jun 2026 | Donepudi Venkata Sohini | BUY | 351 | ₹23.51 lakh |
| 19 Jun 2026 | G. Kelitha | SELL | 300 | ₹20.23 lakh |
| 19 Jun 2026 | G.V.Praneeth | BUY | 300 | ₹20.23 lakh |
| 04 Jun 2026 | Nimmagadda Venkata Anirudh | SELL | 15,800 | ₹10.57 Cr |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- lowseekingalpha.com· 03 Nov 2026, 08:00 pmBaron Emerging Markets Fund Q3 2026 Shareholder Letter
- loweconomictimes.indiatimes.com· 21 Sept 2026, 03:31 pmSunil Singhania-backed Abakkus Flexi Cap Fund increases stake in Dixon Technologies, OFSS, 30 others in August
- mediumcorporate actioneconomictimes.indiatimes.com· 11 Aug 2026, 06:12 amBSE to replace Wipro in Nifty 50 index
- loweconomictimes.indiatimes.com· 03 Aug 2026, 06:25 pmDivi's Laboratories among 7 stocks to hit 52-week highs and surge up to 25% in a month - New Peak
- loweconomictimes.indiatimes.com· 22 Jul 2026, 03:00 pmDomestic formulations, chronic therapies to drive Pharma Q1; US generics remain drag
Concalls & investor presentations
AI-generatedKey takeaway: Divi's Laboratories Limited held an earnings conference on August 1, 2026, to discuss its financial results for the quarter ended June 30, 2026. Management reported a consolidated total income of ₹3,144 crores, up from ₹2,529 crores year-over-year, with profit before tax increasing to ₹1,180 crores compared to ₹733 crores in the previous year. The company highlighted stable volumes in its Generic business, while pricing faced competitive pressures. Management noted ongoing investments in manufacturing capabilities and technology development, particularly in peptides and custom synthesis. The external operating environment remained challenging, particularly due to geopolitical factors affecting supply chains. Management emphasized the importance of maintaining supply continuity and strategic inventory buffers. The discussion included insights into the company's capital expenditure projects, which are nearing completion, and the ongoing commitment to corporate social responsibility initiatives. The session concluded with a Q&A segment addressing various operational and financial queries from participants.
The document presented both positive financial results and challenges in the operating environment.
Sourced from an exchange-filed transcript, dated 06 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Divi's Laboratories Limited held its earnings conference call on May 23, 2026, to discuss its financial performance for the quarter and year ended March 31, 2026. Management reported a consolidated total income of ₹2,986 crores for Q4 and ₹11,067 crores for the full year, with profit after tax of ₹751 crores for the quarter and ₹2,568 crores for the year. The company highlighted stable demand across its generic products and strong customer engagement in its Custom Synthesis segment. Management noted challenges in the supply chain due to geopolitical tensions but emphasized their proactive measures to ensure material availability. They also discussed ongoing investments in technology and capacity expansion, particularly in the peptide business. The management expressed a commitment to double-digit revenue growth while acknowledging the impact of rising raw material costs and pricing pressures in the generic segment. The call concluded with a Q&A session addressing various operational and financial queries from analysts.
The document presented a balanced view of the company's performance and challenges.
Sourced from an exchange-filed transcript, dated 29 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Divi's Laboratories Limited held its earnings conference call on February 11, 2026, to discuss the financial results for the quarter and nine months ended December 31, 2025. Management reported a consolidated total income of ₹2,692 crores for Q3FY2026, up from ₹2,401 crores in the same quarter last year. Profit before tax was ₹780 crores, while profit after tax was ₹583 crores. The company highlighted stable performance in its Generics segment, with strong volume traction despite competitive pricing. In Custom Synthesis, multiple projects are progressing towards commercial volumes. The Nutraceutical segment also performed well, contributing ₹214 crores to revenue. Management noted a successful U.S. FDA inspection at its Choutuppal facility, reaffirming its commitment to quality. The company is focused on operational excellence and prudent capital allocation, with ongoing investments in capacity expansion and backward integration initiatives. The call concluded with a Q&A session addressing various operational and strategic queries.
The document presented a balanced overview of financial performance and operational updates.
Sourced from an exchange-filed transcript, dated 14 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedDivi's Laboratories Limited (DIVISLAB) reported total income of ₹9,550 crores and profit after tax of ₹2,209 crores for FY2024-25, reflecting strong financial performance. The company maintained a debt-equity ratio of 0, indicating no net debt, and achieved key operational metrics such as energy conservation of ~34,870 GJ and water conservation of ~92,130 KL. The auditor highlighted key audit matters related to revenue recognition and capitalization of costs under Ind AS 16. The company has no defaults in loan repayments or regulatory actions, and its governance structure complies with statutory requirements.
- Total income of ₹9,550 crores and profit after tax of ₹2,209 crores for FY2024-25.
- No net debt outstanding as of March 31, 2025, with a debt-equity ratio of 0.
- Key audit matters include revenue recognition and capitalization of costs under Ind AS 16.
- No defaults in loan repayments or regulatory actions noted.
- Compliance with corporate governance and statutory requirements.
Key takeaway: Divi's Laboratories Limited demonstrated strong financial performance in FY2024-25 with robust income and profitability, no debt, and compliance with regulatory and governance standards, supported by key audit matters related to revenue and capitalization practices.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
The company received a demand order of ₹249 under Section 122(2)(b) of the CGST Act, 2017 and interest, and is contesting it in the High Court of Telangana. Additionally, a draft order dated March 20, 2026, under section 144C(1) was received from the assessing officer.
Earlier (1-3 years ago)
The company received a demand order of ₹82 along with 100% penalty under Section 122(2)(b) of the CGST Act, 2017 and interest under section 50 aggregating to ₹249. The company has filed a writ petition with the High Court of Telangana and obtained a stay order on the demand until a final decision is made.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company received a demand order of ₹82 crore along with 100% penalty and interest totaling ₹249 crore under CGST Act, 2017. The company has filed a writ petition and obtained a stay order, but the liability is considered remote based on legal counsel and recent judgments.
Earlier (1-3 years ago)
The company has contingent liabilities related to advances given to entities in which relatives of key management personnel are interested, specifically M/s Sri Lakshmi Constructions and M/s Bheema Infra Solutions Private Limited.
The company is facing a contingent liability related to a disputed excise duty, customs duty, sales tax, service tax, and GST claim. The company received a confirmed demand of C82 along with interest and penalty under the CGST Act, 2017, and has filed a writ petition with the High Court of Telangana to stay the collection until a final decision is made.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company has transactions with M/s Divi's Properties Private Limited and M/s Divi's Biotech Private Limited, which are controlled or jointly controlled by key management personnel.
Earlier (1-3 years ago)
The Company has entered into transactions with related parties in compliance with Sections 177 and 188 of the Act, and details have been disclosed in standalone financial statements as required by Indian Accounting Standard 24.
The company has lease rent and rent deposit transactions with M/s Divi's Biotech Private Limited and M/s Divi's Properties Private Limited, which are companies in which key management personnel have significant influence.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
1.16% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).